Panama govt issues fake drug death tally

25 February 2008

The government of Panama has issued its first official estimate of the number of people killed after a counterfeit ingredient from an unlicensed production site in China was used to produce cough medicines. Out of 174 people known to have been poisoned in 2006 by diethylene glycol, a solvent used to make antifreeze, 115 died (Marketletters passim). Jose Vincente Pachar, the Director of the Public Health Ministry's Institute of Legal Medicine, admitted to the New York Times that "we will never know the full extent" of the problem.

Unofficial estimates range from 184 poisonings with 123 deaths, to over 700. The Panama government has come under considerable local pressure over the issue, partly because the country's public health service mixed the contents of 46 barrels of the antifreeze component into 260,000 bottles of cough syrup. In addition, a protest by the relatives of some of the deceased was broken up by riot police, a move Panama's President Martin Torrijos later described as "sad and lamentable."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight